Cargando…
THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
Disclosure: N. Abrahimi: None. A. Abrahimi: None. N. Terrigno: None. Background: Diabetic ketoacidosis (DKA) is a known adverse effect of SGLT-2 inhibitors. (1) Incidences of euglycemic diabetic ketoacidosis in patients on SGLT-2 inhibitors are reported on less. Clinical Case: A 39-year-old male pas...
Autores principales: | Abrahimi, Nora, Abrahimi, Aryan, Terrigno, Nicole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554680/ http://dx.doi.org/10.1210/jendso/bvad114.820 |
Ejemplares similares
-
THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor
por: Viera Feliciano, Natalia, et al.
Publicado: (2023) -
THU359 A Classical Case Of SGLT-2 Inhibitor Euglycemic Ketoacidosis In A Patient With Glucotoxicity
por: Amankwah, Samuel, et al.
Publicado: (2023) -
Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021) -
PSUN190 Is Euglycemic Diabetic Ketoacidosis an Underrecognized Risk of SGLT2 Inhibitor Utilization?
por: Block, Romy, et al.
Publicado: (2022) -
THU324 Euglycemic Diabetic Ketoacidosis Coinciding With COVID-19 Infection During Pregnancy
por: Alkhathlan, Mujahed, et al.
Publicado: (2023)